AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas

The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.